362697-41-4 Usage
Molecular structure
1-Piperidinecarboxylic acid, 4-[(hydroxyamino)carbonyl]-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]methyl]-, 1,1-dimethylethyl ester is a complex organic compound with multiple functional groups and a specific arrangement of atoms.
Prodrug
It is a prodrug of dabigatran, meaning it is a biologically inactive compound that is converted into the active drug (dabigatran) in the body.
Direct thrombin inhibitor
Dabigatran, the active form of the prodrug, directly inhibits the activity of thrombin, an enzyme responsible for blood clot formation.
Indications
It is used to prevent blood clots and stroke in patients with atrial fibrillation and deep vein thrombosis.
Route of administration
Dabigatran etexilate is administered orally, allowing for easy and convenient treatment.
Conversion in the body
The prodrug undergoes a conversion process in the body, resulting in the formation of the active drug, dabigatran.
Anticoagulant therapy
1-Piperidinecarboxylic acid, 4-[(hydroxyamino)carbonyl]-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]methyl]-, 1,1-dimethylethyl ester represents an important advancement in anticoagulant therapy, providing an effective alternative to traditional anticoagulants.
Ongoing research
The compound continues to be studied for additional potential therapeutic applications, indicating its versatility and potential for further development in the pharmaceutical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 362697-41-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,6,2,6,9 and 7 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 362697-41:
(8*3)+(7*6)+(6*2)+(5*6)+(4*9)+(3*7)+(2*4)+(1*1)=174
174 % 10 = 4
So 362697-41-4 is a valid CAS Registry Number.
362697-41-4Relevant academic research and scientific papers
Synthesis and structure-activity relationship of a novel, achiral series of TNF-α converting enzyme inhibitors
Gilmore, John L.,King, Bryan W.,Harris, Cathy,Maduskuie, Thomas,Mercer, Stephen E.,Liu, Rui-Qin,Covington, Maryanne B.,Qian, Mingxin,Ribadeneria, Maria D.,Vaddi, Krishna,Trzaskos, James M.,Newton, Robert C.,Decicco, Carl P.,Duan, James J.-W.
, p. 2699 - 2704 (2007/10/03)
A novel series of achiral TNF-α converting enzyme (TACE) inhibitors has been discovered. These compounds exhibited activities from 0.35 to 11 nM in a porcine TACE assay and inhibited TNF-α production in an LPS-stimulated whole blood assay with an IC5
Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
-
Page/Page column 47, (2010/11/30)
The present application describes novel β-amino acid derivatives of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, X, Z, Ua, Xa, Ya, Za, R1, R2, R3
Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha
-
, (2008/06/13)
The present application describes novel β-amino acid derivatives of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, X, Z, Ua, Xa, Ya, Za, R1, R2, R3, R4, and R4a are defined in the present specification, which are useful as metalloprotease and/or as TNF-α inhibitors.
